

# CITELINE JAPAN AWARDS

TUESDAY, OCTOBER 21, 2025

THE PALACE HOTEL, TOKYO

## BEST NEW DRUG

**The Best New Drug Award recognizes excellence in pharmaceutical development. In this category, the judges will be looking for the small-molecule, biological, cell/gene therapy, digital therapeutic or vaccine product approved in Japan during the qualifying period that represents the best therapeutic advance in its area.**

Any new product is eligible to enter as long as it was approved in its first indication in Japan between July 1, 2024 - June 30, 2025 even if it has not been launched yet. (Generic and biosimilar products are not eligible.)

Entrants must have played a key role in the development of the nominated product, for example as a sole licensee or co-developer responsible for clinical trials and/or regulatory submissions, and all company members of joint development or joint venture agreements should be disclosed in the application.

Please complete the contact and entry sections and email to Natalia Kay, Global Director of Events.

E: [Natalia.Kay@citeline.com](mailto:Natalia.Kay@citeline.com)

**To enter this category, please answer the following:**

- Brand and generic name, indication, company(ies) involved in its development (if more than one company, please detail the relationship between the parties).
- Date and market of approval and launch
- Mechanism of action. How is this differentiated from other products and how does it represent a step forward?
- Outline evidence for clinical activity, for example summary results from registrational clinical trials. How does this translate into a meaningful therapeutic benefit for patients and over other drugs?
- What is the potential market size of the candidate?

## Details of person submitting the entry:

Entering Company

Name of the person submitting this entry form

Organization of the person submitting this entry form (if different from 'Entering Company')

Email address

Website of Entering Company

References

*Include any links to online references that may support your entry*